Grit Biotherapeutics
PrivateLast Round
Series B
Sep 8, 2023
Total Funding Raised
$75.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Grit Biotherapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in September 2023.
Grit Biotherapeutics is a biopharmaceutical company that develops tumor-infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Grit Biotherapeutics Comparables
Compare Grit Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BioSyngen | 84% | |
| NeogenTC | 83% | |
| KSQ Therapeutics | 79% |
For institutional investors. Book with your work email.
Grit Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2023 | ||||
| Series A Extension | Jul 15, 2021 | ||||
| Series A | Dec 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Grit Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yuanhe Capital | Series B |
| China International Capital Corporation | Series B |
| Liando Investment | Series B |
| MPC | Series B, Series A, Series A Extension |
| Sherpa Healthcare Partners | Series B, Series A |
| Decheng Capital | Series B, Series A, Series A Extension |
| Apricot Capital | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 101% MoM.
- Jul 25, 2026
Monthly visitors increased 78% MoM.
For institutional investors. Book with your work email.
Grit Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Grit Biotherapeutics's valuation, stock price, and market status.
Is Grit Biotherapeutics a public or private company?
Grit Biotherapeutics is a private company.
What is the current stock price of Grit Biotherapeutics?
Grit Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Grit Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Grit Biotherapeutics worth (valuation)?
Valuation information for Grit Biotherapeutics is not publicly available.
Can I buy Grit Biotherapeutics stock?
Grit Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Grit Biotherapeutics's last funding round?
Grit Biotherapeutics's most recent funding round was Series B on September 8, 2023.
Who are the main investors in Grit Biotherapeutics?
Key investors in Grit Biotherapeutics include China International Capital Corporation, Sherpa Healthcare Partners.
Will Grit Biotherapeutics IPO soon?
No public IPO plans have been announced for Grit Biotherapeutics.
How can I track Grit Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Grit Biotherapeutics's shares on secondary markets.